Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

With an estimated 1.5 lakh cases of oral cancer diagnosed annually in India and a high mortality rate due to late detection, ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...